구조모아 (StructureMoa)항암 chemical structure spider web
방문Tcelltech Inc.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103(Tcelltech Inc.)은 B7-H3 표적 세포·유전자 치료로, Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinato. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: novel designs to address small patient numbers and based on an understanding of biology with correlative biological studies.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
B7-H3
Solid Tumors
Recruiting
2026-09-02
Data Confidence · Medium
Development Signal · Watch
Viral vectors, used in all licensed products, provide stable genomic integration and durable
humanized mouse model
novel designs to address small patient numbers and based on an understanding of biology with correlative biological studies
targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen
cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed
payloads, while introducing distinct safety and persistence profiles
biomarker in various malignancies
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
구조화 데이터
xenograft mouse
mouse, mouse
PK
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
Tcelltech Inc.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103(Tcelltech Inc.)은 B7-H3 표적 세포·유전자 치료로, Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinato. Phase 1 안전성·PK 탐색 단계입니다. 선택한 코호트에서 보고된 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: novel designs to address small patient numbers and based on an understanding of biology with correlative biological studies.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
B7-H3
Solid Tumors
Recruiting
2026-09-02
Data Confidence · Medium
Development Signal · Watch
Viral vectors, used in all licensed products, provide stable genomic integration and durable
humanized mouse model
novel designs to address small patient numbers and based on an understanding of biology with correlative biological studies
targets with improved tissue restriction; (2) architectural innovations such as armored CARs, optimized signaling (1XX, 28-ΔIL2RB-z(YXXQ)), and cytokine-arming; (3) combinatorial antigen
cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed
payloads, while introducing distinct safety and persistence profiles
biomarker in various malignancies
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
구조화 데이터
xenograft mouse
mouse, mouse
PK
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.